Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator's choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)

被引：8

作者：

Tannir, N. ^{[1
]}

Formiga, M. N. ^{[2
]}

Agarwal, N. ^{[3
]}

Pal, S. K. ^{[4
]}

Cho, D. ^{[5
]}

George, D. J. ^{[6
]}

Hong, W. ^{[7
]}

Tang, L. ^{[7
]}

Qureshi, A. ^{[8
]}

Tagliaferri, M. A. ^{[9
]}

Zalevsky, J. ^{[7
]}

Penkov, K. D. ^{[10
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX USA

[2] AC Camargo Canc Ctr, Ctr Inter Nacl Pesquisa CIPE, Med Oncol Dept, Sao Paulo, SP, Brazil

[3] Univ Utah Hlth, Huntsman Canc Inst, Oncol Internal Med Dept, Salt Lake City, UT USA

[4] UT, City Hope Comprehens Canc Ctr, Med Oncol & Therapeut Res, Duarte, CA USA

[5] WMC Canc Ctr, Med Oncol Dept, Weirton, WV USA

[6] Duke Univ, Dept Med Oncol, Med Ctr, Durham, NC USA

[7] Nektar Therapeut, Clin Dev, San Francisco, CA USA

[8] Bristol Myers Squibb, Global Clin Dev, Princeton, NJ USA

[9] Nektar Therapeut, Clin Dev Dept, San Francisco, CA USA

[10] Private Med Inst Euromedserv, Gen Dept, St Petersburg, Russia

来源：

关键词：

D O I：

10.1016/j.annonc.2022.08.073

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA68

引用

页码：S1433 / S1433

页数：1